https://www.selleckchem.com/pr....oducts/epacadostat-i
001 and p .05, respectively). The mean BZD dose significantly decreased from baseline to post-ramelteon treatment within the responder group (p .05). This trend was not observed in the non-responder group. Meanwhile, the sleep midpoint of patients with SRED/NES and DSWPD did not significantly change after treatment. Our results indicate that ramelteon is a candidate treatment for SRED/NES. The effects of ramelteon might have occurred primarily through the reduction of BZD rather than through the improvement of s
Like
Comment
Share
